FDA Enforcement Trends: Unauthorized Nicotine Products 2026

In September 2025, U.S. Marshals and ATF agents seized 2.1 million illicit vaping products from 11 companies across seven states. Every one of those companies had already received an FDA warning letter. They kept selling anyway. FDA escalated.

That sweep was part of a pattern that nicotine product manufacturers and their ingredient suppliers need to understand: FDA enforcement in 2026 is shifting from retail-level warnings to supply chain-level interdiction. The agency has $200 million in dedicated enforcement funding, new port-of-entry destruction authority, and a proposed rule tying every imported nicotine product shipment to a specific PMTA tracking number. The paper trail from ingredient to finished product is now the critical compliance artifact.

For ingredient suppliers, the question is no longer whether your customers will face enforcement scrutiny. It is whether the documentation you provide can withstand it.

The Numbers Behind FDA's 2026 Enforcement Posture

In its 2024 year in review, FDA's Center for Tobacco Products reported more than 710 warning letters to firms manufacturing, selling, or distributing unauthorized tobacco products, and more than 800 warning letters to brick-and-mortar and online retailers. Those totals have kept climbing since. A separate tranche has gone specifically to firms dealing in unauthorized non-tobacco nicotine (NTN) products.

The civil money penalty (CMP) pipeline runs alongside the warning letters, with complaints filed against both manufacturers and retailers. FDA does not publish a running total that can be checked at any given moment, so treat any specific figure you see quoted, here or elsewhere, as a snapshot of the date it was published rather than a current count.

The more durable fact is on the authorization side. FDA has not granted marketing authorization to any product marketed as non-tobacco or synthetic nicotine. Every NTN product on the US market is unauthorized under federal law, and FDA has stated the position plainly: all NTN products on the market are marketed unlawfully and risk enforcement action. FDA's list of authorized tobacco products is the reference to check before you accept any supplier's or customer's claim about a product's status.

From Warning Letters to Seizures: How Enforcement Is Escalating

The enforcement escalation pattern follows a predictable sequence: warning letter, follow-up inspection, continued non-compliance, then injunction or seizure. FDA and DOJ have initiated eight permanent injunction proceedings against e-cigarette manufacturers since October 2022. One company, Soul Vapor LLC, was targeted twice.

Port-of-Entry Seizures Set New Records

The most significant enforcement shift in 2025 was at the border. In February 2025, FDA and CBP announced the seizure of approximately 2 million unauthorized e-cigarette units in Chicago, with an estimated retail value of $33.8 million. Nearly all originated in China.

Then in September 2025, the agencies announced a larger operation covering 4.7 million units worth $86.5 million across Arizona, Florida, Georgia, Illinois, New Jersey, and North Carolina. Retail values in seizure announcements are agency estimates of street value, not audited figures, and they are the number that gets quoted rather than the unit count. Taken together the 2025 announcements exceeded 6 million units.

FDA also sent its first-ever import informational letters to 24 tobacco importers and customs entry filers responsible for importing unauthorized products. Many shipments contained vague product descriptions with incorrect declared values, an apparent attempt to evade duties and import review.

Import Alerts Now Enable Detention Without Physical Examination

Updated in January 2025, Import Alert 98-07 covers ENDS products and allows any unauthorized e-cigarette to be detained without physical examination and refused admission. Import Alert 98-06 covers other tobacco products, including unauthorized smokeless tobacco and nicotine pouches. The alerts were separated specifically to give clearer instructions to field staff, customs brokers, importers, and entry filers.

For manufacturers sourcing nicotine ingredients through import channels, these alerts mean that shipment documentation must be precise, complete, and verifiable at the point of entry. Ambiguity in product descriptions or missing authorization data is now a trigger for detention, not just a compliance gap to address later.

$200 Million and a New Interagency Task Force

Section 772 of the FY2026 Agriculture-FDA appropriations legislation directs FDA to spend at least $200 million of tobacco user-fee collections on ENDS enforcement. Set against CTP's overall user-fee budget, that is a decisive tilt toward enforcement over other priorities.

The same provision sets aside $2 million to continue a DOJ-led multi-agency task force targeting illegal ENDS products imported from China and elsewhere, and requires FDA to report to Congress twice a year on progress removing illegal ENDS products from the market. It also required FDA to update its enforcement-priorities guidance within a year of enactment, which is what produced the May 2026 enforcement priorities guidance. Alongside the funding, FDA has gained the practical ability to destroy rather than re-export illegal e-cigarette products seized at ports of entry.

The practical implication: enforcement is no longer constrained by CTP's historically limited staff. Multi-agency coordination brings DHS border resources and DOJ prosecution capacity into the enforcement pipeline. When a nicotine product shipment arrives at a US port without proper documentation, the responding agencies now have authority, funding, and infrastructure to act immediately.

The ACE Tracking Number Rule: Linking Shipments to PMTAs

A proposed rule published in the Federal Register on August 16, 2024 (Docket: FDA-2024-N-1111) would require importers of ENDS products to provide a PMTA Submission Tracking Number (STN) at the time of entry in the Automated Commercial Environment (ACE) system. Currently, providing the STN is optional. The rule would make it mandatory.

Each imported shipment would be directly linked to a specific PMTA application, enabling automated admissibility review by FDA's import systems. Products without a valid STN would be flagged for detention or refusal at the border. The rule would make it "significantly more difficult for unauthorised products to enter the US through legitimate customs channels."

The comment period closed October 15, 2024. As of August 2026 FDA has not issued a final rule, and supplying the tracking number is still optional. Nothing in this proposal binds an importer today. The direction is nevertheless clear: FDA is building toward automated systems that connect product documentation to physical shipments.

Enforcement Is Moving Upstream Through the Supply Chain

The most consequential trend for ingredient suppliers is the directional shift in enforcement targets.

Early enforcement from 2020 through 2023 focused primarily on retailers selling unauthorized products. In February 2023, FDA filed its first CMP complaints against manufacturers. By September 2025, enforcement escalated to distributors, with five targeted in the nationwide seizure sweep. That same year brought the first import informational letters to importers and customs entry filers.

The pattern is unmistakable: enforcement is moving upstream, from point of sale to point of manufacture and import. FDA's own registration and listing modernization efforts reinforce this direction. New Form FDA 3741 consolidates registration forms and adds a Universal Product Code field for traceability. The stated goal is "clearer visibility into who is manufacturing what, where products are being made, and how they move through the supply chain."

For ingredient suppliers, this means your documentation is no longer several steps removed from enforcement activity. When FDA traces an unauthorized product back through its supply chain, the ingredient supplier's records are part of what they find, or fail to find.

The CMP Constitutional Challenge

One complicating factor: on August 1, 2025, the US District Court for the Northern District of Texas held in Wulferic LLC v. FDA that the Tobacco Control Act's civil money penalty provisions violate the Seventh Amendment right to a jury trial, applying the Supreme Court's reasoning in SEC v. Jarkesy. The court declined to issue a nationwide injunction, so the ruling bound only the parties before it. FDA appealed to the Fifth Circuit on September 29, 2025, and the Fifth Circuit heard argument in a companion case on February 2, 2026, with the Wulferic appeal stayed pending that decision. On the same day, a second Northern District of Texas decision, Vaping Dragon LLC v. FDA, reached the same conclusion and ordered dismissal of the administrative complaint against that company.

The circuit has not ruled as of August 2026. If CMPs are ultimately limited by the courts, FDA may lean more heavily on injunctions and seizures, both of which operate at the supply chain level. The net effect could be to accelerate, not slow, the enforcement shift toward manufacturers, distributors, importers, and their suppliers.

What This Means for Ingredient Documentation

FDA enforcement in 2026 is increasingly data-driven, tied directly to PMTA status through Marketing Denial Orders (MDOs) and Refuse to File (RTF) decisions. Regulatory analysts describe it as enforcement "aligned with regulatory outcomes," where MDOs and RTFs serve as a roadmap for targeted enforcement activity.

For nicotine ingredient suppliers, this alignment creates specific documentation requirements. Under 21 CFR Part 1114, PMTA submissions must include for each ingredient: the ingredient name (IUPAC or common chemical name), CAS number, purity and grade with supplier identity, target quantity and range with unit of measure, manufacturing methods and controls, and evidence of batch-to-batch consistency.

Starting January 2, 2026, PMTA and Substantial Equivalence submissions must use the current versions of FDA's application forms (Forms FDA 4057, 4057a, 3965 and 3965a). The web-based versions are optional: updated PDF versions are still accepted. Superseded versions are not, and FDA has said it generally intends to refuse to accept applications that use them.

Eight Documentation Capabilities Your Customers Need From You

Based on current enforcement patterns and PMTA requirements, ingredient suppliers should be able to provide:

1. Certificates of Analysis for every batch. Including purity, grade, contaminant testing, and CAS numbers. A USP/EP grade nicotine CoA with full impurity profiling is the documentation standard FDA expects in PMTA ingredient submissions.

2. Full traceability documentation. Lot numbers, manufacturing dates, and chain of custody from production through delivery. When FDA traces an unauthorized product upstream, this is the documentation trail they follow.

3. Consistent product specifications. Documented target ranges that match what customers declare in their PMTA applications. Specification drift between what the supplier provides and what the PMTA states creates a deficiency that FDA will identify during review.

4. Supplier identity verification. Clear legal entity name, facility addresses, and registration status. The registration modernization efforts are designed to give FDA visibility into exactly this information.

5. Stability and shelf-life data. Supporting long-term product characterization that demonstrates ingredient specifications hold through the product's declared shelf life.

6. USP/EP grade compliance documentation. For pharmaceutical-grade nicotine, this includes monograph compliance records that satisfy both FDA and international regulatory frameworks. Nicotine salts and other derivative forms each require grade-specific documentation.

7. Change notification protocols. A documented process for notifying customers of any specification changes that could affect their PMTA. An undocumented specification change that surfaces during FDA review can trigger a deficiency letter for your customer.

8. Regulatory correspondence readiness. The ability to respond rapidly to FDA information requests during PMTA review. Multi-year reviews routinely generate supplemental information requests. Response time and documentation quality shape how those reviews proceed.

The Supply Chain Accountability Thesis

FDA is moving from what enforcement observers call "whack-a-mole" retail enforcement to structural supply chain controls. The ACE tracking number rule, registration modernization, import alert updates, and the $200 million enforcement budget all create documentation checkpoints throughout the supply chain.

The ingredient supplier sits at a critical node in this chain. Manufacturers who submit PMTAs need their ingredient documentation to be precise, consistent, and auditable. When that documentation comes from a US-based supplier with a certified manufacturing partner, the compliance path is shorter: no import documentation complexity, faster response to FDA supplemental requests, and manufacturing partner audits accessible on shorter notice.

The contrast with undocumented offshore sourcing is stark. Building supply chain traceability retroactively during an active PMTA review is a liability, not a documentation exercise. The PMTA fast-track pilot for nicotine pouches makes the same point from the other direction. The pilot streamlined how FDA runs a review; it did not lower the evidentiary bar. FDA authorized four further on! pouches through it on August 4, 2026, bringing the total number of authorized nicotine pouch products to 30. Every one of those authorizations rests on a full 21 CFR Part 1114 record. There is no lighter pathway, only a faster queue for applications that already have the data.

Ingredient suppliers who provide robust, PMTA-ready documentation give their customers a compliance advantage. When FDA uses MDOs and RTFs as a roadmap for targeted action, that advantage is the difference between a product that survives enforcement scrutiny and one that does not.

If your current ingredient documentation would not survive an FDA trace-back from a finished product to your batch records, that gap needs to close before enforcement reaches your position in the supply chain. NicAlliance provides USP/EP grade nicotine and nicotine dilutions with full batch documentation, CoA transparency, and PMTA-ready traceability records. Request a sample with complete documentation to benchmark against your current supplier's package.

Frequently Asked Questions